3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Recurrence
6
Lymphoma, Mantle-Cell
5
Waldenstrom Macroglobulinemia
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, B-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Hairy Cell
1
Hematologic Neoplasms
1
Burkitt Lymphoma
1
Interventions
zanubrutinib
9
ibrutinib
9
Rituximab
5
idelalisib
4
venetoclax
3
pirtobrutinib
3
ublituximab
2
bazlitoran
2
acalabrutinib
2
Dexamethasone
2
ARQ531
2
umbralisib
1
selinexor
1
sapanisertib
1
pomalidomide
1
perifosine
1
pembrolizumab
1
ontuxizumab
1
ofatumumab
1
obinutuzumab
1
mavorixafor
1
loncastuximab tesirine
1
fludarabine
1
epratuzumab
1
enzastaurin
1
carfilzomib
1
brexucabtagene autoleucel
1
WW Domain-Containing Oxidoreductase
1
Voriconazole
1
Vitamin B 12
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Waldenstrom Macroglobulinemia
×
brexucabtagene autoleucel
×
Clear all
NCT05537766
2026-03-10
ZUMA-25
Gilead Sciences
Phase 2
Terminated
19 enrolled
28 charts